Progress on novel agents treating childhood primary immune thrombocytopenia
10.3760/cma.j.issn.2095-428X.2017.15.003
- VernacularTitle:儿童原发性免疫性血小板减少症新药研发进展
- Author:
Weiqun XU
- Keywords:
Thrombocytopenia;
Immunity;
Primary;
New drugs;
Child
- From:
Chinese Journal of Applied Clinical Pediatrics
2017;32(15):1129-1132
- CountryChina
- Language:Chinese
-
Abstract:
The mechanisms of childhood primary immune thrombocytopenia(ITP) are the destruction of platelet by platelet antibody and cytotoxic T cells,which also influence the function of megakaryocyte and cause the reduction of platelet.Novel agents targeted to the immune abnormalities of ITP includes 4 types:(1) CD40-CD154 pathway blocker,such as humanized CD154 antibody Toralizumab,which is monoclonal antibody and modify Fc,hopefully to be used in treatment of ITP.(2) The drugs which block the binding between Fc receptor and anti-platelet antibody such as Rozrolimupab,which is the combination of 25 kinds of anti-RHD and presents 62％ efficacy but has severe hemolysis as adverse effects which restricts the application on ITP.Soluble FcγRⅡb(SM101) is also effective on ITP and it conquer the shortcome of activating of B cells to induce autoimmune diseases.(3) The drugs which block the key molecular Syk of activation the platelet phagocytosis by microphage such as R788,with 44％ effectiveness.(4)The drugs which stimulate thrombopoiesis such as Avatrombopag et al.
